论文部分内容阅读
目的探讨增殖诱导配体(a proliferation-inducing ligand,APRIL)在原发性肝癌组织中的表达及其与临床病理生理特点的关系。方法采用实时荧光定量PCR检测原发性肝癌患者癌组织、癌旁组织和远端相对正常组织APRILmRNA的表达,并研究其与肝癌的病理生理特点的关系。结果原发性肝癌癌组织APRIL mRNA的表达水平为0.58±0.10,远高于癌旁组织的0.22±0.09(P<0.01),多个肿瘤病灶的肝癌组织APRILmRNA的水平为0.64±0.09,高于单个肿瘤病灶的肝癌组织APRILmRNA的水平0.53±0.11(P<0.05)。结论APRIL在原发性肝癌的进展过程中可能起到一定程度的促进作用,对抗APRIL功能在抗癌治疗中可能具有潜在的作用。
Objective To investigate the expression of a proliferation-inducing ligand (APRIL) in primary hepatocellular carcinoma (HCC) and its relationship with clinicopathological features. Methods Real-time fluorescent quantitative PCR was used to detect the expression of APRIL mRNA in primary liver cancer tissues, adjacent non-cancerous tissues and distal normal tissues. The relationship between the expression of APRIL mRNA and the pathophysiological characteristics of hepatocellular carcinoma was also studied. Results The mRNA expression of APRIL in primary hepatocellular carcinoma was 0.58 ± 0.10, much higher than that in adjacent tissues (0.22 ± 0.09, P <0.01). The level of APRIL mRNA in multiple tumor tissues was 0.64 ± 0.09 The level of APRIL mRNA in hepatocarcinoma with a single tumor lesion was 0.53 ± 0.11 (P <0.05). Conclusion APRIL may play a role in promoting the progression of primary hepatocellular carcinoma to a certain extent, and it may play a potential role in anti-cancer therapy against APRIL.